Akebia Reports Lower Q4 Vafseo Revenue Due to Inventory Adjustment, Advances Rare Kidney Disease Pipeline
Summary
Akebia Therapeutics reported Q4 2025 Vafseo net product revenue significantly below underlying demand due to an inventory adjustment, while also announcing progress in its rare kidney disease pipeline.
Key Events
-
Q4 Vafseo Revenue Miss
Reported Q4 2025 Vafseo net product revenue of $5-$6 million, significantly below the underlying patient dosing demand of $10.5-$11.5 million.
-
Inventory Adjustment Impact
The revenue shortfall was primarily attributed to a $4.5-$5 million decrease in channel inventory at U.S. Renal Care (USRC) centers due to a new observed dosing protocol.
-
Pipeline Advancement
Initiated a Phase 2 clinical trial for Praliciguat in Focal Segmental Glomerulosclerosis (FSGS) and plans to start a Phase 2 basket study for AKB-097 in rare kidney diseases in 2H 2026.
-
Commercial Progress & Outlook
Secured Vafseo prescribing access for approximately 275,000 patients and expects revenue growth to resume in Q1 2026.
Analysis
Akebia Therapeutics reported Q4 2025 Vafseo net product revenue of $5-$6 million, which is substantially lower than the underlying patient dosing demand of $10.5-$11.5 million. This significant near-term financial disappointment, attributed to a channel inventory adjustment and occurring while the stock trades near its 52-week low, could pressure shares. However, the company anticipates revenue growth to resume in Q1 2026 and highlighted significant progress in its pipeline, including the initiation of a Phase 2 trial for Praliciguat and plans for a Phase 2 basket study for AKB-097, which are positive long-term developments for a life sciences company.
At the time of this filing, AKBA was trading at $1.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $395.4M. The 52-week trading range was $1.45 to $4.08. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.